Biosergen publish financial report for second quarter ahead of schedule.

Biosergen announces today that the company will publish the quarterly financial report for Q2 2023 ahead of schedule on August 14 instead of August 31 as previously communicated.

For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net

Certified Adviser
Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se

ABOUT BIOSERGEN

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders.  Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005’s potential as a game-changing antifungal treatment.  Biosergen’s development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.